Johnson & Johnson (NYSE:JNJ) Stock Position Raised by Lbmc Investment Advisors LLC

Lbmc Investment Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 12.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,630 shares of the company’s stock after purchasing an additional 864 shares during the period. Lbmc Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,265,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $32,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $33,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $36,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.9%

JNJ stock opened at $154.99 on Monday. The business has a 50-day moving average of $154.31 and a 200-day moving average of $153.66. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $372.92 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.36%. Johnson & Johnson’s dividend payout ratio is 57.84%.

Analyst Ratings Changes

A number of analysts have issued reports on JNJ shares. Morgan Stanley raised their target price on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Wednesday, April 16th. Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, April 10th. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 22nd. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Leerink Partnrs lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.